Your browser doesn't support javascript.
loading
Post-remission measurable residual disease directs treatment choice and improves outcomes for patients with intermediate-risk acute myeloid leukemia in CR1.
Han, Lijie; Li, Yilu; Wu, Jiaying; Peng, Jie; Han, Xiaolin; Zhao, Hongmian; He, Chen; Li, Yuanyuan; Wang, Weimin; Zhang, Mengmeng; Li, Yafei; Sun, Hui; Cao, Haixia; Sang, Li'na; Jiang, Zhongxing; Yu, Jifeng.
Afiliación
  • Han L; Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. hanlijiede@126.com.
  • Li Y; Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
  • Wu J; Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
  • Peng J; Department of Oncology, The Second Affiliated Hospital of Guizhou Medical University, Kaili, China.
  • Han X; Department of Hematology, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, China.
  • Zhao H; Department of Hematology, Huaihe Hospital of Henan University, Kaifeng, China.
  • He C; Laboratory of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
  • Li Y; School of Foreign Languages, Henan University of Chinese Medicine, Zhengzhou, China.
  • Wang W; Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
  • Zhang M; Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
  • Li Y; Laboratory of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
  • Sun H; Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
  • Cao H; Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
  • Sang L; Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
  • Jiang Z; Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
  • Yu J; Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. yujifengzzu@163.com.
Int J Hematol ; 116(6): 892-901, 2022 Dec.
Article en En | MEDLINE | ID: mdl-36031670
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Leucemia Mieloide Aguda / Trasplante de Células Madre Hematopoyéticas Tipo de estudio: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Int J Hematol Asunto de la revista: HEMATOLOGIA Año: 2022 Tipo del documento: Article País de afiliación: China
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Leucemia Mieloide Aguda / Trasplante de Células Madre Hematopoyéticas Tipo de estudio: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Int J Hematol Asunto de la revista: HEMATOLOGIA Año: 2022 Tipo del documento: Article País de afiliación: China